Shanghvi Gives Sun An M&A Dose Of Growth
Pharma billionaire sees 63% rise in net worth as acquisitions pay off.
sun pharma
September 2024
January 2024
December 2023
September 2023
January 2023
December 2022
November 2022
September 2022
Dilip Shanghvi Richest Pharma Entrepreneur
Sun Pharma chairman leads the pack with a net worth of ₹2.32 lakh cr; Cyrus Poonawalla follows with ₹1.71 lakh crore.
Sun Pharma buys outstanding stake in Taro for ₹2,891 cr
The transaction marks the conclusion of a nearly 17-year effort to gain full control of the U.S.-listed generic drugmaker
Sun Pharma shares hit 52-week high on acquiring Israeli company
As per the regulatory filing by the pharmaceutical major, through the acquisition, Sun Pharma aims to facilitate the consolidation of business in Israel.
Sun Pharma revises offer to buy outstanding shares of Taro Pharma; stock falls
Sun proposes to acquire outstanding shares of Taro’s at $43 apiece, up from $38 per share earlier
Suzlon shares fall 3% as Sun Pharma's Shanghvi terminates investor agreement
Dilip Shanghvi family and associate companies terminated shareholders' agreement with Suzlon, which was signed in February 2020.
Sun Pharma to buy U.S. drug firm Concert for $576 mn
The upfront payment of $8 per share of common stock in cash represents a premium of around 33% to Concert's 30-day volume weighted average price as of January 18, 2023.
Sun Pharma gets U.S. FDA warning for Halol facility; share falls 2%
The pharma company received a warning letter from the U.S. FDA for violations of manufacturing standards at the Halol facility in Gujarat.
Sun Pharma Q2 profit rises 10.5% to ₹2,262 cr; revenue up 13%
Sun Pharma MD Dilip Shanghvi says in Q2, Sun Pharma recorded double-digit topline growth and strong margins, driven by market share gain in India, and sustained ramp-up of global specialty biz.
Surprise! Despite Covid-19 sales, Indian pharma an underperformer
A majority of pharma stocks reported double digit negative returns, while the overall market (BSE Sensex) delivered a 9% plus return.
